Dermata Therapeutics Shares Are Trading Over 100%: What You Need To Know

Dermata Therapeutics, Inc. DRMA shares are trading north of 105% at last check Wednesday, and experiencing several trading halts. Here’s what you need to know.

What Happened: Last week, the company announced it has enrolled 50% of patients in its pivotal Phase 3 STAR-1 clinical trial for a once-weekly topical acne treatment.

This milestone is crucial as the company aims to release topline results in the first quarter of 2025.

The treatment, DMT310, would be the first once-weekly topical product approved for treating moderate-to-severe acne if successful.

Currently, 30 million patients seek treatment annually.

The Phase 3 program includes two trials evaluating the efficacy, safety and tolerability of DMT310. Previous Phase 2b results showed promising improvements in acne symptoms, with nearly 45% of patients achieving clear or almost clear skin.

How To Buy Dermata Therapeutics Shares?

Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange-traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Dermata‘s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

DRMA Price Action: Dermata Therapeutics shares are currently trading at $2.67, according to Benzinga Pro.

Now Read:

• Roper Technologies Surpasses Q2 Earnings Estimates

Image: Shutterstock/ solarseven.